Investorideas.com - Actively Trading Pharma/Biotech Stocks: OTCVolumeleaders.com Reports on OTCBB Market ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: BOPH), (OTCBB: ACCP), (OTCBB: QPSA)

Investorideas.com - Actively Trading Pharma/Biotech Stocks: OTCVolumeleaders.com Reports on OTCBB Market ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: BOPH), (OTCBB: ACCP), (OTCBB: QPSA)



Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial


Subscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) September 22, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include CONTINENTAL MINERALS (OTCBB: KMKCF), Bohai Pharmaceuticals Group, Inc. (OTCBB: BOPH), Access Pharmaceuticals Inc. (OTCBB: ACCP), and Quepasa Corp. (OTCBB: QPSA).




Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
OTC/Market Commentary:
One of the OTCBB volume leader reports; Recent News: "Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. Coinciding with the signing of the above agreement, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals ("Jian An") Limited in Shenzhen, China in an effort to leverage Jian An's extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan."
Full Article: http://finance.yahoo.com/news/Access-Pharmaceuticals-Inc-prnews-1403730987.html?x=0&.v=1

Market Snapshot: (at time of release)
Dow 10,746.39 -14.64 -0.14%
Nasdaq 2,333.63 -15.72 -0.67%
S&P 500 1,135.01 -4.77 -0.42%
10 Yr Bond(%) 2.5480% -0.4600
Oil 74.69 -0.28 -0.37%
Gold 1,290.00 +17.60 +1.38%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/

Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader


* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC

Investors - Get OTC stock quotes from http://www.otcmarkets.com

Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX), Inc. To Present at the JMP Healthcare Conference

Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX), Inc. To Present at the JMP Healthcare Conference


Visit this company: www.biosantepharma.com

LINCOLNSHIRE, Ill. - September 22, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the JMP Healthcare Conference being held in the New York Palace Hotel, New York City from September 27-28, 2010.


Phillip B. Donenberg, BioSante's senior vice president of finance and CFO, will speak on Monday, September 27 at 1:00 pm ET. Mr. Donenberg will provide a status update on BioSante's lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante.


About the JMP Healthcare Conference
JMP Securities presents its fifth annual healthcare industry conference, an institutional investor forum featuring more than 100 leading publicly traded and privately held companies in the areas of biotechnology, medical devices and healthcare services and facilities.



About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.




Contact:
BioSante Pharmaceuticals
For Media:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
For Investors:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
Visit the BPAX showcase profile at Investorideas.com Request News and Info on BPAX Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Investorideas.com - Actively Trading Biotech and Pharmaceutical Stocks: OTCVolumeleaders.com Reports on OTCBB Market ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: BOPH), (OTCBB: ENHD), (OTCBB: AVXL)

Investorideas.com - Actively Trading Biotech and Pharmaceutical Stocks: OTCVolumeleaders.com Reports on OTCBB Market ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: BOPH), (OTCBB: ENHD), (OTCBB: AVXL)

Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleadersNote to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERSCategory: Investment, FinancialSubscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com

Point Roberts, WA (Investorideas.com Newswire) September 21, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include CONTINENTAL MINERALS (OTCBB: KMKCF), Bohai Pharmaceuticals Group, Inc. (OTCBB: BOPH), Energroup Holdings Corp. (OTCBB: ENHD), Anavex Life Sciences Corp. (OTCBB: AVXL).

Sign up for Tomorrows Hot OTC Market Leaders Today! http://bit.ly/otcvolumeleadersOTC/Market Commentary:One of the OTCBB volume leader reports; Recent News: "Bohai Pharmaceuticals Group, a TCM pharmaceutical company, said it has added five marketed products to its portfolio so far this year, bringing its total to ten. Bohai holds the rights to produce another 14 TCM formulations in China.Three of the newly introduced products are prescription drugs, while the remaining two are OTC medicines. The new products will complement Bohai's flagship offerings, Tongbi Capsules and Tablets and Lung Nourishing Cream, which were added to the National Drug Reimbursement list in late 2009."Full Article: http://seekingalpha.com/article/225881-bohai-pharma-doubles-portfolio-products?source=yahooMarket Snapshot: (at time of release)Dow 10,734.55 -19.07 -0.18%
Nasdaq 2,345.72 -10.11 -0.43%
S&P 500 1,137.60 -5.11 -0.45%
10 Yr Bond(%) 2.6650% -0.4100
Oil 73.01 -1.69 -2.26%
Gold 1,275.80 -3.20 -0.25%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/


Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader

* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC SecuritiesVisit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.More Info:Published at www.Investorideas.com - Global research by sectorsIf you have any questions regarding information in this press release please contact the company listed in the press release.Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Investorideas.com - Q&A Interview with BioSante Pharmaceuticals (NASDAQ: BPAX), A Company Focused on Female Sexual Health and Oncology

Investorideas.com - Q&A Interview with BioSante Pharmaceuticals (NASDAQ: BPAX), A Company Focused on Female Sexual Health and Oncology


Stephen M. Simes, President and Chief Executive Officer, Discusses Potential of Leading Product, LibiGel

Subscribe to Investor Ideas Newswire
Visit this company: www.biosantepharma.com
September 21, 2010 -(Investorideas.com newswire) www.InvestorIdeas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, presents a Q&A interview with BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following the sector.

Q: Investorideas.com
Can you give investors a brief overview of your current focus in the pharmaceutical market?

A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Today, BioSante is focused on development of our LibiGel which is in late-stage Phase III clinical studies for the treatment of female sexual dysfunction, for which there is no FDA approved pharmaceutical product. In addition we have a full pipeline of pharmaceutical products in clinical trials for various indications focused on women's health, as well as a portfolio of cancer vaccines being developed.

Q: Investorideas.com
One of your leading products, LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) is positioned to be a market leader and a pioneer in the making. Can you discuss the potential in terms of market value and how it compares to Viagra breaking into the male market over twelve years ago?

A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Interestingly and unfortunately women still do not have an FDA approved pharmaceutical product to help with their sexual functioning issues, notwithstanding the fact that men have had Viagra for over 12 years. BioSante hopes to change that with our LibiGel. We expect that LibiGel will be the first product approved for the treatment of this true unmet medical need of hypoactive sexual desire disorder. Market research indicates that the market for a product for women actually is larger than the male products which today are about $2 billion per year in sales.

Q: Investorideas.com
LibiGel is currently in late-stage Phase III clinical studies. Can you give investors a brief overview of what is next and the potential timelines?

A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
LibiGel is in three Phase III clinical studies. We hope to complete enrollment in these studies this year and to submit a new drug application (NDA) to the FDA by the end of next year for an approval an d launch in 2012. The time has come for women to have a product for treatment of this unmet medical need and BioSante is committed to bringing LibiGel to market for the treatment of females sexual dysfunction.

Q: Investorideas.com
For Investors following the LibiGel clinical development program, can you give investors perspective and confidence on the company's ability to move forward from a cash position?

A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Despite the very difficult markets and economy we all have lived through these last several years, BioSante has raised over $70 million in the last year. As of June 30, 2010 we reported over $40 million in the bank. We burn about $3 million per month conducting the tree LibiGel clinical studies and running our company. Therefore we are in a good financial position to implement the plans I have discussed. We believe our ability to raise a significant sum in these difficult days is a major statement by investors in the potential value of LibiGel for women.

Q: Investorideas.com
Separate from LibiGel®, your company has products in development for the oncology market. Can you give investors a brief update on the status of your cancer vaccines?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
BioSante is in development of a full pipeline of cancer vaccines to treat various forms of cancer. The lead vaccines are for breast cancer, pancreatic cancer and leukemia. We have received orphan drug designation for the latter two forms of cancer which is valuable to BioSante from a commercial point of view. Interestingly the cancer vaccines are in about 15 clinical trials today at minimal cost to BioSante since they are funded by others interested in bringing improved cancer therapies to patients in need.
BioSante (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.


Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/Or the company website www.biosantepharma.com to learn more about BioSante.
Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up page: http://www.investorideas.com/Resources/Newsletter.asp


*BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) is brought to Investorideas.com by Money Channel TV http://www.moneychannel.tv/
About the Money Channel:
About our Biuotech/Pharma Stocks portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.Visit the Biotech stocks Directory
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.


Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (seven hundred fifty per month) Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising.

http://www.investorideas.com/About/Disclaimer.aspDisclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Learn about Investor Protection and Regulation for Pinks sheets
For info about BioSante Pharmaceuticals, Inc
Contact:The Trout Group LLCTricia Swanson(646) 378-2953; tswanson@troutgroup.com
For Additional Information about Investorideas.com:
C Van Zant: 800-665-0411 – cvanzant@investorideas.com

Investorideas.com - Biotech/Pharma Stocks: OTCVolumeleaders.com Reports on Actively Trading OTC Stocks ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: AVXL), (OTCBB: IBPM), (OTCBB: FNCB)

Investorideas.com - Biotech/Pharma Stocks: OTCVolumeleaders.com Reports on Actively Trading OTC Stocks ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: AVXL), (OTCBB: IBPM), (OTCBB: FNCB)



Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial

Subscribe to Investor Ideas Newswire


Visit this company: www.otcvolumeleaders.com


Point Roberts, WA (Investorideas.com Newswire) September 17, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include CONTINENTAL MINERALS (OTCBB: KMKCF), Anavex Life Sciences Corp. (OTCBB: AVXL), IBIOPHARMA, INC. (OTCBB: IBPM), and First National Community Bancorp Inc. (OTCBB: FNCB).

Sign up for Tomorrows Hot OTC Market Leaders Today!http://bit.ly/otcvolumeleaders


OTC/Market Commentary:
Sectors include Biotech Stocks
One of the OTCBB volume leader reports; Anavex Life Sciences Corp. (OTCBB: AVXL): "Anavex Life Sciences Corp. (www.anavex.com) is a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases and cancer. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves the rational design of drug compounds that are targeted to specific receptors involved in the modulation of multiple cellular biochemical signaling pathways.


ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drug candidates that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, pain). The company's lead drug candidates exhibit high affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated anti-amnesic and neuroprotective properties."

Market Snapshot: (at time of release)
Dow 10,614.25 +19.42 +0.18%
Nasdaq 2,317.07 +13.82 +0.60%
S&P 500 1,127.04 +2.38 +0.21%
10 Yr Bond(%) 2.7520% -0.0700
Oil 73.66 -0.91 -1.22%
Gold 1,275.60 +3.70 +0.29%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Investorideas.com - Biotech/Pharma Stocks; Most Actively Trading OTC Stocks; ($0.14-$0.25): (OTCBB: NCEN), (OTCBB: SNBP), (OTCBB: STTN), (OTCBB: HDVY)

Investorideas.com - Biotech/Pharma Stocks; Most Actively Trading OTC Stocks; ($0.14-$0.25): (OTCBB: NCEN), (OTCBB: SNBP), (OTCBB: STTN), (OTCBB: HDVY)


Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial


Subscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com



Point Roberts, WA (Investorideas.com Newswire) September 16, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($0.14-$0.25) Nacel Energy Corporation (OTCBB: NCEN), Sinobiopharma, Inc. (OTCBB: SNBP), Smart-Tek Solutions Inc. (OTCBB: STTN), and Health Discovery Corp. (OTCBB: HDVY).




Sign up for Tomorrows Hot OTC Market Leaders Today!http://bit.ly/otcvolumeleaders


OTC/Market Commentary:
Sectors include Biotech Stocks
One of the OTCBB volume leaders; Sinobiopharma, Inc. (OTCBB: SNBP); "Sinobiopharma is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., Sinobiopharma's wholly-owned subsidiary in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Sinobiopharma has patented new methods for synthesizing active pharmaceutical ingredients (API) at a lower cost and owns drug delivery formulations that improve usability. For additional information, please visit the Company's website at: www.sinobp.com."

(OTCBB: AQUM)
Market Snapshot: (at time of release)
Dow 10,573.98 +1.25 +0.01% Nasdaq 2,296.24 -5.08 -0.22% S&P 500 1,122.02 -3.05 -0.27% 10 Yr Bond(%) 2.7460% +0.2300 Oil 74.63 -1.39 -1.83% Gold 1,274.80 +8.10 +0.64%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Trading News; Top Twenty Gaining Stocks on NASDAQ September 13th;Top Four; (OTIX), (GTSI), (OCCF), (ARST)

Trading News; Top Twenty Gaining Stocks on NASDAQ September 13th


Top Four; (OTIX), (GTSI), (OCCF), (ARST)

September 13, 2010 (Investorideas.com Newswire) http://www.investorideas.com/ reports on the top 20 gainers as of the close of September 13th as investors look at opening markets for the 14th. Biotech/Pharma, Banks and Tech dominated the gainers. Investors enjoyed another up day in the market following positive Chinese economic data.


Investorideas.com is an investor research portal specialized in sector investing, covering over twenty sectors including Biotech/Pharma stocks, tech stocks and China stocks.

Twenty Most Advanced NASDAQ Stocks :
Symbol Company Last Sale* Change Net / % Share Volume
(OTIX): OTIX Global, Inc $ 8.34, up 4.30 106.44% on 2,759,963 shares



(GTSI): GTSI Corp. $ 6.89, up 1.71 33.01% on 361,480 shares



(OCCF): Optical Cable Corporation $ 2.78, up 0.58 26.36% on 91,890 shares



(ARST) : Arc Sight, Inc. $ 43.91, up 8.81 25.10% on 8,828,531 shares



(XNPT) : XenoPort, Inc. $ 7.55, up 1.35 21.77% on 1,515,927 shares



(SOGB): Southcoast Financial Corporation $ 3.49, up 0.62 21.60% on 13,447 shares



(CARV): Carver Bancorp, Inc. $ 3.73, up 0.62 19.94% on 3,438 shares



(SNTA): Synta Pharmaceuticals Corp. $ 3.72 , up 0.55 17.35% on 434,065 shares



(EOSPN): EOS Preferred Corporation $ 20.40, up 2.89 16.50% on 13,815 shares



(PATK): Patrick Industries, Inc. $ 2.4499, up 0.3399 16.11% on 18,404 shares



(INFI): Infinity Pharmaceuticals, Inc. $ 5.95, up 0.81 15.76% on 36,140 shares



(FURX): Furiex Pharmaceuticals, Inc. $ 11.46 , up 1.52 15.29% on 384,379 shares



(ZIONN): Zions Bancorporation $ 6.45, up 0.85 15.18% 0n 26,500 shares



(GENT):Gentium SpA $ 6.42, up 0.82 14.64% on 136,751 shares



(OSBCP): Old Second Bancorp, Inc. $ 3.26 , up 0.41 14.39% on 69,621 shaes



(NVMI): Nova Measuring Instruments Ltd. $ 5.27 , up 0.63 13.58% on 425,614 shares



(MDMD): MediaMind Technologies Inc. $ 13.62, up 1.57 13.03% on 121,281 shares



(TDSC): 3D Systems Corporation $ 14.61 1.67 12.91% 61,383



(CLDX:) Celldex Therapeutics, Inc $ 3.94, up 0.45 12.89% on 1,221,546 shares



(GCMO): Globecomm Systems Inc. $ 7.85, up 0.84 11.98% on 99,072 shares

About www.investorIdeas.com: Sector research for independent investors
Investor Ideas is a global investor research portal specialized in sector investing, providing in-depth research, news, investor tools and stock directories for energy stocks, renewable energy, homeland security, water, gold / mining stocks, nanotech stocks, biotech and other leading sectors. Investor Ideas Members currently get login access to 11 stock directories including all energy stock directories. Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/


Get free investor newsletters and stock alerts at Investorideas.com

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.aspDisclosure - http://www.investorideas.com/About/News/Clientspecifics.asp
Contact us at 800 - 665 -0411 or cvanzant@investorideas.com